Want to see CVM full AI Analyst Report?
CVM Stock Chart & Stats
$5.19
-$0.03(-7.92%)
At close: 4:00 PM EST
$5.19
-$0.03(-7.92%)
Day’s Range― - ―
52-Week Range$0.89 - $13.48
Previous Close$0.36
Volume1.47M
Average Volume (3M)125.69K
Market Cap
$23.59M
Enterprise Value$14.18M
Total Cash (Recent Filing)$1.89M
Total Debt (Recent Filing)$8.51M
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.47
Shares Outstanding17,477,144
10 Day Avg. Volume66,836
30 Day Avg. Volume125,686
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.34
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.54
Enterprise Value/Ebitda-0.77
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4.16
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
GMP Manufacturing CapabilityOwning GMP bioprocessing facilities and offering contract development/manufacturing provides a durable, non‑clinical revenue stream. This service capability diversifies funding sources, leverages technical know‑how, and can generate milestone and batch revenues that moderate funding dependence while supporting long‑term operational scale.
Middle East Commercial PartnershipA formal distribution and revenue‑sharing agreement with Amarox creates a tangible commercialization pathway in a defined region. Regional partner expertise can accelerate regulatory submissions, market entry, and reimbursement planning, lowering execution risk and improving the long‑term odds of generating product sales from Multikine if trials succeed.
Parallel Regulatory StrategyLaunching a confirmatory registration study and pursuing dual U.S./Saudi regulatory tracks materially advances the program from development toward potential approval. Parallel pathways diversify regulatory risk, allow staggered commercialization, and, if successful, create sustainable product revenue opportunities and allow staged market rollouts.
Bears Say
No Product RevenueAs a pre‑commercial biotech with zero product revenue, CEL‑SCI relies on financing and service contracts to fund R&D. Persistent operating losses mean there is no internal cash generation to fund development, keeping the company dependent on external capital and exposing shareholders to dilution and execution risk over the next several months.
Consistent Cash BurnSustained negative operating and free cash flow at ~‑$18M+ annually creates a structural funding requirement. Continued cash burn forces recurring financings or monetization of assets, which can be dilutive or costly, and constrains the firm's ability to scale trials or commercial operations without securing reliable, long‑term capital sources.
Balance Sheet Comparability RiskA materially different TTM balance sheet with increased absolute debt and assets introduces uncertainty about capital structure and obligations. This structural change complicates forecasting and leverage assessment, may reflect recent financings or non‑recurring items, and raises the risk that future cash commitments or covenants could restrict operations.
Cel-Sci News
CVM FAQ
What was Cel-Sci Corp.’s price range in the past 12 months?
Cel-Sci Corp. lowest stock price was $0.89 and its highest was $13.48 in the past 12 months.
What is Cel-Sci Corp.’s market cap?
Cel-Sci Corp.’s market cap is $23.59M.
When is Cel-Sci Corp.’s upcoming earnings report date?
Cel-Sci Corp.’s upcoming earnings report date is Aug 17, 2026 which is in 36 days.
How were Cel-Sci Corp.’s earnings last quarter?
Cel-Sci Corp. released its earnings results on May 18, 2026. The company reported -$0.67 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.67.
Is Cel-Sci Corp. overvalued?
According to Wall Street analysts Cel-Sci Corp.’s price is currently Overvalued.
Does Cel-Sci Corp. pay dividends?
Cel-Sci Corp. does not currently pay dividends.
What is Cel-Sci Corp.’s EPS estimate?
Cel-Sci Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cel-Sci Corp. have?
Cel-Sci Corp. has 17,477,144 shares outstanding.
What happened to Cel-Sci Corp.’s price movement after its last earnings report?
Cel-Sci Corp. reported an EPS of -$0.67 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 20.28%.
Which hedge fund is a major shareholder of Cel-Sci Corp.?
Currently, no hedge funds are holding shares in CVM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cel-Sci Corp.
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
Technical Analysis
Ownership Overview
3.59% Insiders
1.84% Mutual Funds
0.04% Other Institutional Investors
91.42% Public Companies and
Individual Investors